Albireo Pharma Inc
ALBO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$915.89M
Close$
$57.06
29.2% upside
Current Fair Value
29.2% upsideUndervalued by 29.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $915.89 Million |
|---|---|
| Enterprise Value | $693.41 Million |
| Earnings per Share | $-7.87 |
| Beta | 1.04 |
| Outstanding Shares | 19,655,000 |
Return
| Return on Equity | -131.05% |
|---|---|
| Return on Assets | -40.83% |
| Return on Invested Capital | -39.74% |
Valuation & Multiples
| P/E Ratio | -5.61 |
|---|---|
| PEG | 3.38 |
| Price to Sales | 22.08 |
| Price to Book Ratio | 8.83 |
| Enterprise Value to Revenue | 12.08 |
| Enterprise Value to EBIT | -6.16 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Institutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%0% |
|---|---|
| Total Invested | $44 |
| Investors Holding | 10% |
About Albireo Pharma Inc
CEO: Ronald Cooper
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product ...